A citation-based method for searching scientific literature

Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M Schram, Helen H Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena, Srushti Kittane, Fan Wu, Yanyan Cai, Sabrina Arena, Benedetta Mussolin, Ram Kannan, Neil Vasan, Alexander N Gorelick, Michael F Berger, Ofra Novoplansky, Sankar Jagadeeshan, Yi Liao, Uwe Rix, Sandra Misale, Barry S Taylor, Alberto Bardelli, Jaclyn F Hechtman, David M Hyman, Moshe Elkabets, Elisa de Stanchina, Chandra S Verma, Andrea Ventura, Alexander Drilon, Maurizio Scaltriti. Cancer Discov 2021
Times Cited: 16







List of co-cited articles
138 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
193
75

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, Nora Ku, Brian B Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R Kolakowski, Barbara J Brandhuber,[...]. Cancer Discov 2017
219
62

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
56

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
552
56

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
195
43

TRKing down an old oncogene in a new era of targeted therapy.
Aria Vaishnavi, Anh T Le, Robert C Doebele. Cancer Discov 2015
350
43

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Robert C Doebele, Lara E Davis, Aria Vaishnavi, Anh T Le, Adriana Estrada-Bernal, Stephen Keysar, Antonio Jimeno, Marileila Varella-Garcia, Dara L Aisner, Yali Li,[...]. Cancer Discov 2015
248
43

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
449
37

Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Emiliano Cocco, Alison M Schram, Amanda Kulick, Sandra Misale, Helen H Won, Rona Yaeger, Pedram Razavi, Ryan Ptashkin, Jaclyn F Hechtman, Eneda Toska,[...]. Nat Med 2019
90
37

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
132
31

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard,[...]. Ann Oncol 2019
147
31

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, D M Hyman, J Hechtman, G Wei,[...]. Ann Oncol 2016
188
31

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
395
31

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
James P Solomon, Irina Linkov, Andrea Rosado, Kerry Mullaney, Ezra Y Rosen, Denise Frosina, Achim A Jungbluth, Ahmet Zehir, Ryma Benayed, Alexander Drilon,[...]. Mod Pathol 2020
197
25

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Theodore W Laetsch, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin Rudzinski, Angela M Feraco,[...]. Lancet Oncol 2018
276
25

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena. ESMO Open 2016
295
25

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
633
25

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Zofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, Justin F Gainor, Inga T Lennes, Viola W Zhu, Nicolas Marcoux, Mandeep K Banwait, Subba R Digumarthy, Wenjia Su,[...]. Cancer Discov 2018
213
25


Inhibiting TRK Proteins in Clinical Cancer Therapy.
Allison M Lange, Hui-Wen Lo. Cancers (Basel) 2018
89
25

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima,[...]. Nat Commun 2019
61
25

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
89
25

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Romel Somwar, Nicolle E Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S Mattar, Elisa de Stanchina,[...]. Commun Biol 2020
15
26

Trk receptors: roles in neuronal signal transduction.
Eric J Huang, Louis F Reichardt. Annu Rev Biochem 2003
18

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
175
18

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
829
18

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
285
18

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu,[...]. Cancer Discov 2017
455
18

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Justin Taylor, Dean Pavlick, Akihide Yoshimi, Christina Marcelus, Stephen S Chung, Jaclyn F Hechtman, Ryma Benayed, Emiliano Cocco, Benjamin H Durham, Lillian Bitner,[...]. J Clin Invest 2018
34
18

Recent Advances in Targeting ROS1 in Lung Cancer.
Jessica J Lin, Alice T Shaw. J Thorac Oncol 2017
127
18

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, Ryohei Katayama, Yuki Shimizu, Viola W Zhu, Thomas Yang Sun, Heather A Wakelee, Russell Madison, Alexa B Schrock,[...]. Clin Cancer Res 2020
28
18

Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Mark M Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D Falk, Sergei Timofeevski,[...]. N Engl J Med 2013
242
18

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon,[...]. Clin Cancer Res 2016
88
18

Anchored multiplex PCR for targeted next-generation sequencing.
Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, Yi Cao, Divya Panditi, Kerry D Lynch, Juxiang Chen, Hayley E Robinson, Hyo Sup Shim, Juliann Chmielecki,[...]. Nat Med 2014
535
18

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, Benjamin J Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski,[...]. Cancer Discov 2018
142
18

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
Ryosuke Okamura, Amélie Boichard, Shumei Kato, Jason K Sicklick, Lyudmila Bazhenova, Razelle Kurzrock. JCO Precis Oncol 2018
164
18

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
D S Hong, T M Bauer, J J Lee, A Dowlati, M S Brose, A F Farago, M Taylor, A T Shaw, S Montez, F Meric-Bernstam,[...]. Ann Oncol 2019
46
18

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, Mari Mino-Kenudson, Benjamin J Solomon, Balazs Halmos, Nicholas A Jessop, John C Wain, Alan Tien Yeo, Cyril Benes,[...]. Sci Transl Med 2012
920
18

Functional characterization of human cancer-derived TRKB mutations.
Thomas R Geiger, Ji-Ying Song, Aranzazu Rosado, Daniel S Peeper. PLoS One 2011
31
18

Oncogenes in solid human tumours.
S Pulciani, E Santos, A V Lauver, L K Long, S A Aaronson, M Barbacid. Nature 1982
467
18

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.
Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen, Liang Ouyang. Acta Pharm Sin B 2021
28
18

Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Wei Yan, Lingtian Zhang, Fengping Lv, Marialuisa Moccia, Francesca Carlomagno, Christophe Landry, Massimo Santoro, Fabien Gosselet, Brendan Frett, Hong-Yu Li. Eur J Med Chem 2021
9
33


Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
Zongliang Liu, Pengfei Yu, Lin Dong, Wenyan Wang, Sijin Duan, Bingsi Wang, Xiaoyan Gong, Liang Ye, Hongbo Wang, Jingwei Tian. J Med Chem 2021
7
42

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Miho J Fuse, Koutaroh Okada, Tomoko Oh-Hara, Hayato Ogura, Naoya Fujita, Ryohei Katayama. Mol Cancer Ther 2017
55
18

Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Brion W Murray, Evan Rogers, Dayong Zhai, Wei Deng, Xi Chen, Paul A Sprengeler, Xin Zhang, Armin Graber, Siegfried H Reich, Shanna Stopatschinskaja,[...]. Mol Cancer Ther 2021
7
42

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
475
12

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
432
12

Structural basis for the action of the drug trametinib at KSR-bound MEK.
Zaigham M Khan, Alexander M Real, William M Marsiglia, Arthur Chow, Mary E Duffy, Jayasudhan R Yerabolu, Alex P Scopton, Arvin C Dar. Nature 2020
34
12

Larotrectinib followed by selitrectinib in a novel DCTN1-NTRK1 fusion undifferentiated pleomorphic sarcoma.
Xue Na Goh, Michaela Su-Fern Seng, Amos Hong Pheng Loh, Achint Gupta, Kenneth Tou En Chang, Prasad Iyer. J Oncol Pharm Pract 2021
3
66


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.